These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 9218700)
1. Antithrombotic effects in a rat model of aspirin-insensitive arterial thrombosis of desethyl KBT-3022, the main active metabolite of a new antiplatelet agent, KBT-3022. Shimazawa M; Takiguchi Y; Umemura K; Kondo K; Nakashima M Eur J Pharmacol; 1997 Jun; 328(2-3):183-9. PubMed ID: 9218700 [TBL] [Abstract][Full Text] [Related]
2. Inhibitory effects of the new anti-platelet agent KBT-3022 and its metabolite on rabbit neutrophil function in vitro. Yokota K; Yamamoto N; Obata Y; Oda M Jpn J Pharmacol; 1996 Apr; 70(4):291-302. PubMed ID: 8847836 [TBL] [Abstract][Full Text] [Related]
3. The mechanism of action of KBT-3022, a new antiplatelet agent. Matsuo K; Yokota K; Yamashita A; Oda M Gen Pharmacol; 1997 Feb; 28(2):229-35. PubMed ID: 9013200 [TBL] [Abstract][Full Text] [Related]
4. Effect of KBT-3022, a new diphenylthiazole derivative, on platelet functions. Yokota K; Yamamoto N; Morimoto Y; Yamashita A; Oda M J Pharm Pharmacol; 1995 Sep; 47(9):768-74. PubMed ID: 8583391 [TBL] [Abstract][Full Text] [Related]
5. [Determination of the main metabolite (desethyl KBT-3022) of a new antiplatelet agent, KBT-3022 in plasma by gas chromatography]. Nakada Y; Shimada H; Awata N Yakugaku Zasshi; 1992 Jun; 112(6):414-7. PubMed ID: 1432594 [TBL] [Abstract][Full Text] [Related]
6. Effect of KBT-3022, a new cyclooxygenase inhibitor, on experimental brain edema in vitro and in vivo. Yamamoto N; Yokota K; Yamashita A; Oda M Eur J Pharmacol; 1996 Feb; 297(3):225-31. PubMed ID: 8666054 [TBL] [Abstract][Full Text] [Related]
7. Anti-thrombotic activity of KBT-3022 in experimental models of thrombosis. Yokota K; Yamashita A; Oda M Jpn J Pharmacol; 1995 Jun; 68(2):201-6. PubMed ID: 7563977 [TBL] [Abstract][Full Text] [Related]
8. Inhibitory effect of KW-3635, a new thromboxane A2-receptor antagonist, on arterial thrombosis in guinea pigs. Higo K; Karasawa A Jpn J Pharmacol; 1993 Dec; 63(4):521-3. PubMed ID: 8121085 [TBL] [Abstract][Full Text] [Related]
9. A ferret model of electrical-induction of arterial thrombosis that is sensitive to aspirin. Schumacher WA; Steinbacher TE; Megill JR; Durham SK J Pharmacol Toxicol Methods; 1996 Feb; 35(1):3-10. PubMed ID: 8645878 [TBL] [Abstract][Full Text] [Related]
10. Comparison of the inhibitory effects of the TXA2 receptor antagonist, vapiprost, and other antiplatelet drugs on arterial thrombosis in rats: possible role of TXA2. Takiguchi Y; Wada K; Nakashima M Thromb Haemost; 1992 Oct; 68(4):460-3. PubMed ID: 1448780 [TBL] [Abstract][Full Text] [Related]
11. Antithrombotic effect of a novel recombinant hirudin analogue, CX-397, in a rat arterial thrombosis model. Takiguchi Y; Asai F; Wada K; Hayashi H; Nakashima M Br J Pharmacol; 1995 Dec; 116(7):3056-60. PubMed ID: 8680743 [TBL] [Abstract][Full Text] [Related]
12. Superiority of platelet integrin GPIIb-IIIa receptor antagonist over aspirin in preventing cyclic flow reductions in the guinea pig middle cerebral artery. Kawano K; Ikeda Y; Kondo K; Umemura K Eur J Pharmacol; 1999 Jun; 374(3):377-85. PubMed ID: 10422782 [TBL] [Abstract][Full Text] [Related]
14. A comparative study of the antithrombotic effect of aurintricarboxylic acid on arterial thrombosis in rats and guinea pigs. Takiguchi Y; Shimazawa M; Nakashima M Br J Pharmacol; 1996 Aug; 118(7):1633-8. PubMed ID: 8842425 [TBL] [Abstract][Full Text] [Related]
15. Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist. Mousa SA; Bozarth JM; Forsythe MS; Jackson SM; Leamy A; Diemer MM; Kapil RP; Knabb RM; Mayo MC; Pierce SK Circulation; 1994 Jan; 89(1):3-12. PubMed ID: 8281661 [TBL] [Abstract][Full Text] [Related]
16. Antithrombotic and platelet function inhibiting effects of ML3000, a new antiinflammatory drug with Cox/5-LOX inhibitory activity. Tries S; Laufer S; Radziwon P; Breddin HK Inflamm Res; 2002 Mar; 51(3):129-34. PubMed ID: 12005203 [TBL] [Abstract][Full Text] [Related]
17. Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation. Rotondo S; Krauze-Brzósko K; Manarini S; Evangelista V; Cerletti C Eur J Pharmacol; 2004 Mar; 488(1-3):79-83. PubMed ID: 15044038 [TBL] [Abstract][Full Text] [Related]
18. Vicagrel enhances aspirin-induced inhibition of both platelet aggregation and thrombus formation in rodents due to its decreased metabolic inactivation. Jia YM; Ge PX; Zhou H; Ji JZ; Tai T; Gu TT; Zhu T; Li YF; Mi QY; Huang BB; Xie HG Biomed Pharmacother; 2019 Jul; 115():108906. PubMed ID: 31060007 [TBL] [Abstract][Full Text] [Related]
19. Antiplatelet and antithrombotic effects of YM337, the Fab fragment of a humanized anti-GPIIb/IIIa monoclonal antibody in monkeys. Kaku S; Kawasaki T; Hisamichi N; Sakai Y; Taniuchi Y; Inagaki O; Yano S; Suzuki K; Terazaki C; Masuho Y; Satoh N; Takenaka T; Yanagi K; Ohshima N Thromb Haemost; 1996 Apr; 75(4):679-84. PubMed ID: 8743199 [TBL] [Abstract][Full Text] [Related]
20. Inhibitory effect of KBT-3022, a new anti-platelet agent, on infiltration of polymorphonuclear leukocytes induced by leukotriene B4 or formyl-methionyl-leucyl-phenylalanine in mice. Yokota K; Yamamoto N; Obata Y; Oda M Jpn J Pharmacol; 1995 Jul; 68(3):353-7. PubMed ID: 7474560 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]